Thermo Fisher Scientific UFD1L Monoclonal Antibody (OTI3E9), TrueMAB

Applications

• Western Blot (WB): Tested at 1:2,000 dilution

Product Specifications

Target Information

Ubiquitin-mediated proteolysis requires the transfer of ubiquitin (Ub) to lysine groups on selected cellular proteins, which then potentiates the proteolytic degradation of these protein conjugates by the 26S proteasome. Ub-fusions are cleaved by Ub-specific processing proteases (UBps) or alternatively by the Ub-fusion degradation (UFD) pathway.
The UBP pathway targets the C-terminal glycine residue on Ub involved in the formation of Ub-conjugates, while UFD proteins preferentially cleave Ub-conjugated proteins that contain an amino acid substitution at this glycine residue.
The UFD1 protein was originally characterized in S. cerevisiae and subsequently, the human homolog UFD1 or UFD1L was identified. In vitro, UFD1 attenuates degradation of Ub-fusions with proline or valine substitution at the Gly76 moiety by selective multiubiquitination of the Ub chain.
Mutations within the UFD1 gene are implicated in CATCH22 syndrome, characterized by cardiac defects, cleft palate, and hypocalcemia, suggesting involvement of this proteolytic pathway in developmental defects.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.